ALLMedicine™ Ependymoma Center

Oct 23rd, 2021 - Malignant brain tumors are among the most intractable cancers, including malignancies such as glioblastoma, diffuse midline glioma, medulloblastoma, and ependymoma. Unfortunately, treatment options for these brain tumors have been inadequate and c...

Oct 23rd, 2021 - Posterior fossa type A (PFA) ependymomas have 2 molecular subgroups (PFA-1 and PFA-2) and 9 subtypes. Gene expression profiling suggests that PFA-1 and PFA-2 tumors have distinct developmental origins at different rostrocaudal levels of the brains...

Oct 10th, 2021 - Gliomas represent the most frequent central nervous system (CNS) tumors in children and adolescents. However, therapeutic strategies for these patients, based on tumor molecular profile, are still limited compared to the wide range of treatment op...

Oct 5th, 2021 - More than 40% of patients with intracranial ependymoma need a salvage treatment within 5 years after diagnosis, and no standard treatment is available as yet. We report the outcome after first relapse of 64 patients treated within the 2 nd AIEOP p...

Oct 2nd, 2021 - Few studies report outcomes in children treated with radiation for non-myxopapillary ependymoma of the spinal cord, and little evidence exists to inform decisions regarding target volume and prescription dose. Moreover, virtually no mature outcome...

Sep 29th, 2021 - Stratum 1: This is a phase 2 single-arm open-label study that will define event-free survival (EFS) and overall survival (OS) following therapy with irinotecan, temozolomide, bevacizumab, and compartmental (intraOmmaya) radioimmunotherapy (cRIT) 1...

Sep 5th, 2021 - Background: There are more than 130 identified primary tumors of the central nervous system (CNS). Most have an annual incidence of less than 1000 in the United States. Given the rarity of each of the tumors listed above, there is a paucity of pro...

Apr 30th, 2021 - This study plans to detect the presence of trastuzumab by mass spectroscopy in relapsed posterior fossa ependymoma (PFEPN) tumor specimen pre-treated with a single dose of intrathecal (IT) trastuzumab, as well as to evaluate toxicity of intratheca...

Dec 21st, 2020 - This study seeks to determine the optimum dose frequency of 5-Azacytidin (5-AZA) infusions into the fourth ventricle of the brain. The study's primary objective is to establish the maximum tolerated dose for infusions of 5-Azacytidine into the fou...

Jul 17th, 2020 - The study will consist of 4 parallel groups of participants, one for each of the following primary brain tumor types: high-grade glioma, medulloblastoma, ependymoma and DIPG. A Simon's Optimal two-stage study design will be applied to each group a...

Apr 14th, 2021 - The FDA has granted a rare pediatric disease (RPD) designation to the p-STAT3 inhibitor WP1066 for the treatment of patients with ependymoma, a rare type of tumor that can develop in the brain or the spinal cord.1 The FDA’s recognition of the h...

Dec 20th, 2020 - Mark R. Gilbert, MD The deployment of precision medicine to develop safe and effective therapies to treat malignant brain tumors is an endeavor eagerly embraced by researchers and patients alike, but the effort poses both opportunities and challe...

Dec 20th, 2020 - Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses radiation therapy for young children under the age of 3 who have ependymoma. He highlighted outcomes of the 10-year-long SJYC07 trial at the 2018 ASCO Annua...

Dec 4th, 2020 - Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses drug development for pediatric patients with brain tumors. Drug development is challenging, explains Upadhyaya, especially as it relates to pediatric patie...

Dec 4th, 2020 - Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses risk factors for developing pediatric ependymoma. Most pediatric patients who are diagnosed with ependymoma are diagnosed without any known predisposition ...